These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1756627)

  • 1. Clinical trial with 3-keto-desogestrel subdermal implants.
    Díaz S; Pavez M; Moo-Young AJ; Bardin CW; Croxatto HB
    Contraception; 1991 Oct; 44(4):393-408. PubMed ID: 1756627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial with Nestorone subdermal contraceptive implants.
    Díaz S; Schiappacasse V; Pavez M; Zepeda A; Moo-Young AJ; Brandeis A; Lähteenmäki P; Croxatto HB
    Contraception; 1995 Jan; 51(1):33-8. PubMed ID: 7750282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results with subcutaneous implants containing 3-keto desogestrel.
    Olsson SE; Odlind V; Johansson E
    Contraception; 1990 Jul; 42(1):1-11. PubMed ID: 2117514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release kinetics of 3-keto-desogestrel from contraceptive implants (Implanon) in dogs: comparison with in vitro data.
    Geelen JA; van der Wardt JT; Voortman G; Maassen GC; Eenink MJ
    Contraception; 1993 Feb; 47(2):215-26. PubMed ID: 8449020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
    Back DJ; Grimmer SF; Shenoy N; Orme ML
    Contraception; 1987 Jun; 35(6):619-26. PubMed ID: 2959449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.
    Olsson SE; Odlind V
    Contraception; 1990 Nov; 42(5):563-72. PubMed ID: 2272184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel.
    Jackson R; Newton JR
    Contraception; 1989 Jun; 39(6):653-64. PubMed ID: 2752753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.
    Apter D; Cacciatore B; Stenman UH; Alapiessa U; Assendorp R
    Contraception; 1990 Sep; 42(3):285-95. PubMed ID: 2149697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal implants: contraception for a new century.
    Darney PD
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1536-43. PubMed ID: 8178903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings.
    Timmer CJ; Apter D; Voortman G
    Contraception; 1990 Dec; 42(6):629-42. PubMed ID: 2150632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
    Haukkamaa M; Laurikka-Routti M; Heikinheimo O; Moo-Young A
    Contraception; 1992 Jan; 45(1):49-55. PubMed ID: 1591921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New knowledge in the physiology of hormonal contraceptives.
    Lobo RA; Stanczyk FZ
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levonorgestrel and progesterone levels in women treated with silastic covered rods containing levonorgestrel.
    Croxatto HB; Díaz S; Brandeis A; Pavez M; Johansson ED
    Contraception; 1985 Jun; 31(6):643-54. PubMed ID: 3930143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subdermal norethindrone pellets -- a method for contraception?
    Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
    Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel.
    Hasenack HG; Bosch AM; Käär K
    Contraception; 1986 Jun; 33(6):591-6. PubMed ID: 2945700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.
    Laurikka-Routti M; Haukkamaa M
    Fertil Steril; 1992 Dec; 58(6):1142-7. PubMed ID: 1459263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III clinical trial with a new oral contraceptive containing 150 micrograms desogestrel and 20 micrograms ethinylestradiol.
    Lammers P; op ten Berg M
    Acta Obstet Gynecol Scand; 1991; 70(6):497-500. PubMed ID: 1837199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.